The Portnoy Law Firm has initiated an investigation into HCA Healthcare for possible securities fraud and may file a class action on behalf of investors. The investigation follows HCA's July 14, 2026 press release that significantly downgraded its full-year 2026 earnings outlook, citing an adverse shift in payer breakdown due to a surge in uninsured patient visits that erased roughly $400 million in quarterly revenue. HCA revised its full-year earnings forecast to a range of $28.70 to $30.50 per share, tightened revenue guidance to between $77 billion and $79.5 billion, and scaled back adjusted EBITDA expectations to $15.4 billion to $16.1 billion. Following these disclosures, HCA's stock fell $27.14 per share, or 6.95%, to close at $363.60 on July 14, 2026. Investors are encouraged to contact the firm to discuss their legal rights.
HCA Healthcare, Inc.HCA downgraded its full-year 2026 earnings outlook due to a surge in uninsured patient visits, erasing $400 million in quarterly revenue.